|

TDM for Optimized Outcome in Patients With mRCC.

RECRUITINGSponsored by Niels Fristrup
Actively Recruiting
SponsorNiels Fristrup
Started2020-11-01
Est. completion2028-08-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04659343

Summary

The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients. Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients in Denmark with medically treated metastatic renal cell carcinoma.

Exclusion Criteria:

* No written informed consent.

Conditions6

CancerDrug MechanismDrug Side EffectDrug ToxicityKidney CancerRenal Cell Carcinoma Metastatic

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.